Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Large B-Cell, Diffuse 60Lymphoma 57Lymphoma, Non-Hodgkin 54Lymphoma, Follicular 43Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 26Lymphoma, B-Cell 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 16Recurrence 16Hodgkin Disease 13Multiple Myeloma 9Lymphoma, Large-Cell, Immunoblastic 9Hematologic Neoplasms 8Leukemia, Myeloid, Acute 7Neoplasms, Plasma Cell 6Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Prolymphocytic 6Lymphoma, T-Cell 5Intraocular Lymphoma 5Leukemia, Hairy Cell 4Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, B-Cell 3

Interventions

ublituximab 1Rituximab 1LFB-R603 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myelitis, Transverse × Rituximab × Clear all
NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

University of California, San Francisco

Phase 1 Completed
20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡